Seres Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MCRB research report →
About the company
Seres Therapeutics, Inc. is a pioneering microbiome therapeutics firm dedicated to engineering bacterial consortia that modulate host cells and tissues to combat various diseases. Their flagship therapeutic, SER-109, an oral microbiome treatment, has successfully concluded Phase III clinical trials for the management of Clostridioides difficile infection (CDI).
- CEO
- Richard N. Kender
- IPO
- 2015
- Employees
- 103
- HQ
- Cambridge, MA, US
Price Chart
- Market Cap
- $74.95M
- P/E
- -1.49
- P/S
- 65.35
- P/B
- 2.80
- EV/EBITDA
- -3.00
- Div Yield
- 0.00%
- Gross Margin
- -20.92%
- Op Margin
- -7640.98%
- Net Margin
- -4088.84%
- ROE
- -127.30%
- ROIC
- -80.30%
- Revenue
- $789.00K · 0.00%
- Net Income
- $5.70M · 103.89%
- EPS
- $0.64 · 103.39%
- Op Income
- $-93,971,000
- FCF YoY
- 100.58%
- 52W High
- $29.98
- 52W Low
- $5.31
- 50D MA
- $7.30
- 200D MA
- $12.59
- Beta
- 0.10
- Avg Volume
- 70.75K
Get TickerSpark's AI analysis on MCRB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 1, 26 | Berenson Stephen | other | 7,508 |
| Jul 1, 26 | Rosiello Robert L. | other | 7,508 |
| Jul 1, 26 | Ausiello Dennis A | other | 7,508 |
| May 15, 26 | Shaff Eric D. | other | 722 |
| May 18, 26 | Shaff Eric D. | sell | 259 |
| May 15, 26 | DesRosier Thomas | other | 244 |
| May 18, 26 | DesRosier Thomas | sell | 79 |
| May 15, 26 | Shaff Eric D. | other | 331 |
| May 15, 26 | Shaff Eric D. | other | 391 |
| May 15, 26 | DesRosier Thomas | other | 111 |
Our MCRB coverage
Recent articles, reports, and earnings notes.
No research on MCRB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MCRB report →Similar companies
Peers in the same neighborhood.